By Ed Frankl

Bayer AG said Friday that European drug regulators recommended its finerenone kidney-disease treatment for marketing authorization in the EU.

The German pharmaceutical company said the Committee for Medicinal Products for Human Use, a branch of the European Medicines Agency, gave a positive opinion for finerenone as a new treatment of chronic kidney disease associated with type 2 diabetes in adults.

"The positive CHMP opinion for finerenone brings us closer to providing this new treatment option to patients with chronic kidney disease associated with type 2 diabetes," said Christian Rommel, Bayer's head of pharmaceuticals research and development.

The regulatory opinion is based on the results of a Phase 3 study investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in more than 13,000 patients.

Finerenone was approved by the U.S. Food and Drug Administration in July 2021 under the brand name Kerendia.

Write to Ed Frankl at edward.frankl@dowjones.com

(END) Dow Jones Newswires

12-17-21 0759ET